arpo buy eye optim approach treat diabet nephropathi
initi coverag buy rate
messag arpo ve-ptp inhibitor evalu phase studi patient non-prolif diabet
retinopathi npdr differenti attribut includ potenti first-in-class new mechan action administ
system via subcutan inject util multipl complic pathway target play critic role vascular
stabil clinic pre-clin evid improv measur retinopathi nephropathi million
patient suffer npdr current treatment optim initi coverag arpo buy rate pt
first-in-class small molecul ve-ptp inhibitor could improv vascular stabil activ essenti
vascular stabil keep activ inhibit ve-ptp mechanist could util one
complic diabet diabet retinopathi dr diabet nephropathi dn driven microvascular damag
sinc stabil blood vessel wall prevent vascular leakag could first self-administ system
deliv treatment dr
phase data show favor outcom npdr potenti dn phase studi evalu
without lucenti patient diabet macular edema dme combin demonstr statist signific reduct
central subfield thick cst monotherapi produc similar improv diabet retina sever score drss
lucenti combin retrospect analysi also demonstr improv uacr patient receiv
on-going phase studi could show improv drss uacr arpo expect result studi
evalu once- twice-daili vs placebo patient npdr primari endpoint measur improv
drss week secondari endpoint evalu uacr believ chanc improv drss high especi
sinc durat longer confirm improv uacr like bring paradigm-shift favor
earlier stage pipelin could anoth upsid driver arpo could also pursu develop antibodi target ve-ptp
could allow greater dose develop flexibl could also develop glaucoma partner
advanc inflammatori bowel disord arpo could requir financ advanc pipelin
market opportun could larg channel check indic dr underserv patient diagnos npdr
us eu japan per arpo anoth patient undiagnos current avail drug intravitr inject use
patient dr dme accord doctor could penetr expand npdr market estim peak
sale composit matter patent expir could extend hatch-waxman extens
current valuat leav room upsid price target blend two methodolog sum-of-the-part dcf
valu methodolog believ relev development-stag compani price-to-earnings multipl base
approach upsid case scenario assum higher sale gener compel benefit nephropathi
impli valu could high per share posit news flow includ result studi could
take valuat higher
page analyst certif import disclosur
eye optim approach treat diabet retinopathi initi buy rate
initi coverag inc buy rate
price target arpo lead product candid small
molecul inject ve-ptp inhibitor phase studi
treatment non-prolif diabet retinopathi npdr on-going
arpo expect phase result follow start phase
studi view valu proposit lie potenti
first treatment diabet retinopathi could
administ via subcutan inject date drug approv
treatment dr avail intravitr inject
limit use doctor offic increas rate diabet us
world-wide along complic diabet diseas diabet
retinopathi increas need new access treatment
option chronic disord also hold potenti address
vascular complic diabet model peak sale
us year launch believ arpo profit stand-
alon compani also attract potenti acquisit target
compani target either ophthalm cardiometabol disord
mad studi top-line data ibd
studi data npdr
poc data ibd
top-line data glaucoma
top-line data ibd
initi studi ndpr
could fail demonstr adequ compel efficaci
safeti trial npdr
fda competit could rais clinic bar approv creat
hurdl commerci accept
patient and/ physician may slow uptak
arpo could requir addit capit advanc pipelin
page analyst certif import disclosur
tabl content
what call
 what go
facet
patent life
thing need
page analyst certif import disclosur
page analyst certif import disclosur
slide summari what call believ address
yet unmet need diabet retinopathi larg market opportun
arpo daili subcutan inject diabet retinopathi dr provid
altern current vegf treatment regim requir intravitr inject often
month channel check indic intravitr inject use dr
especi without diabet macular edema dme benefit diabet nephropathi anoth
result diabet vascular complic arpo earlier stage pipelin could drive
upsid believ opportun justifi buy rate
compani without revenu profit histori prefer product level dcf arpo
may also attract acquisit target phase studi success
page analyst certif import disclosur
wholli own target attract market phase data
ophthalmolog focus lead drug phase studi market cap
potenti first-in-class system deliv ve-ptp inhibitor
on-going phase trial patient moderate-to-sever non-prolif diabet
data previous conduct phase studi patient dme
potenti addit benefit indic beyond retinopathi nephropathi
subcutan inject dosag form allow arpo target wider market
patient administ chronic therapi asymptomat diseas home
larg market opportun diagnos patient npdr us anoth
patient undiagnos per arpo mani world-wide
fulli own patent protect potenti
catalyt news flow like near-term top-lin data phase studi
page analyst certif import disclosur
pipelin target sever larg diseas area potenti deliv
small molecul ve-ptp inhibitor deliv via subcutan inject
current test npdr studi
human monoclon antibodi direct target
addit formul develop form eye drop test
patient glaucoma
target ibd develop gossam arpo potenti earn
mileston royalti
given work go forward arpo could potenti target
diseas associ diabet diabet nephropathi
page analyst certif import disclosur
diabet retinopathi npdr phase plannedprimari open-angl bowel diseas ibd gossam macular degener dme pdrpre-clinicaldiabet vascular complic
price volum chart readout could
page analyst certif import disclosur
slide summari arpo manag deep scientif
previous senior advisor invest firm pdl biopharma manag director
skylin ventur gener partner tvm capit ceo
joseph gardner phd presid founder
found arpo spin akebia dec ceo took arpo
round financ lead candid trial previous work
discoveri develop proctor
guid earli pre-clin clinic develop current lead
scientif discoveri previous group medic director cv metabol
diseas bristol-my squibb head therapeut angiogenesi research
proctor gambl pg associ professor medicin pharmacolog duke
respons pre-clin clinic develop regulatori affair medic
affair year experi ophthalmolog focus compani
also lead inventor jetrea approv
previous cfo sever publicli trade healthcar compani acorda
bg medicin bgmd indevu advanc health avl-za autoimmun
page analyst certif import disclosur
slide summari could first system deliv
treatment diabet retinopathi potenti nephropathi
could potenti first treatment diabet retinopathi dr
administ via subcutan inject sinc mechan action target vascular
complic may also improv diabet nephropathi dn
high blood glucos high blood pressur lead vascular damag activ
essenti vascular stabil inhibit ve-ptp small molecul
activ pathway
activ maintain integr endotheli cell junction enhanc endotheli
cell function viabil inhibit vascular inflamm
pathway also seen valid via neutral
phase data demonstr improv disord relat vascular
complic diabet diseas diabet retinopathi potenti diabet
mechan action reduc vascular damag restor vascular integr
system administr allow treatment eye exposur organ
system kidney
arpo own world-wide right
phase studi complet patient dme
page analyst certif import disclosur
phase studi evalu patient diabet macular
edema dme studi look treat fellow eye
evalu activ patient type type diabet
decreas vision due dme
object determin whether combin roch
rhhbi lucenti ranibizumab would lead greater reduct dme treatment
lucenti alon primari endpoint chang baselin cst week
secondari endpoint includ chang baselin bcva chang baselin
diabet retinopathi sever score drss safeti toler
also pre-specifi plan analysi fellow eye base system
exposur combin subset patient monotherapi
page analyst certif import disclosur
outcom dme patient best receiv combin
lucenti therapi base chang cst
studi combin suppress vascular endotheli growth factor
vegf anti-vegf intravitr inject activ via ve-ptp inhibit
led significantli greater chang central subfield thick cst
patient dme seen anti-vegf alon
week mean chang baselin cst greatest combin
lucenti arm /- mm follow lucenti arm
/- mm smallest arm /- mm
mean cst percentag eye resolv edema /- mm
respect combin arm vs /- mm
respect lucenti arm week
treat alon patient show reduct
other show increas cst overal mean chang
page analyst certif import disclosur
vision outcom best dme patient treat anti-vegf
mean chang baselin bcva letter
eye show improv least letter line
combin lucenti arm respect vs lucenti
monotherapi arm respect
page analyst certif import disclosur
comparison visual outcom month subject efficaci chang bcva bl line subject line subject best correct visual acuiti bl baselin biotechnolog
outcom measur use drss similar dme patient receiv
monotherapi combin therapi lucenti
arpo also analyz sever diabet
retinopathi dr eye non-prolif
mean drss similar across three arm
baselin /- combin
lucenti arm /- lucenti
/- arm
improv drss studi eye similar
across three group
patient treat show posit
effect fellow eye percentag qualifi
fellow eye chang
plu lucenti arm
compar
lucenti monotherapi group
fellow eye background dr
treat local vegf suppress system
monotherapi
combin lucenti group
fellow eye background dr
page analyst certif import disclosur
appear gener toler studi
major advers event report mild moder sever
twelv patient sever monotherapi arm lucenti
monotherapi arm combin lucenti arm none
seriou consid drug-rel
common ocular worsen dme visual acuiti vitreou
floater major occur observ period fellow eye
page analyst certif import disclosur
summari ocular treatment-emerg advers event report subject safeti populationadvers eventeventssubjectseventssubjectseventssubjectsdiabet retin edema wors period period acuiti reduc period period floater period period monotherapi monotherapi combin
slide summari what go chang arpo
expect arpo report phase result data posit
lead appreci arpo share
arpo conduct one phase studi patient npdr
trial design includ expect endpoint improv drss
primari endpoint novel endpoint chang renal function secondari
clinic regulatori event expect per arpo
phase result subcutan inject expect around
could report phase result ulcer coliti around
phase data drop glaucoma studi could avail
phase trial could start
could advanc pivot stage test patient npdr
 and/or partnership possibl taken place ophthalmolog arena
back eye market remain commerci attract current assum arpo
seek partner result demonstr strong benefit retinopathi nephropathi
page analyst certif import disclosur
arpo facet differenti
page analyst certif import disclosur
facet differenti novel target
ang/ pathway play role maintain vascular integr
transmembran receptor found endotheli cell phosphoryl activ
essenti vascular stabil
maintain integr endotheli cell junction
enhanc endotheli cell function viabil
lead vascular destabil
promot patholog vascular leak neovascular
tyrosin kinas protein activ secret pericyt
patient diabet inactiv upregul vascular endothelial-
protein tyrosin phosphatas ve-ptp express endotheli cell ang-
level angiopoietin ve-ptp increas hypoxia lead
accentu vegf-medi ocular neovascular vascular leakag
inhibit ve-ptp therebi activ even presenc work
separ independ activ antibodi develop
roch rhhbi nc regeneron neutral
page analyst certif import disclosur
directli modul ve-ptp indirectli
angiopoietin stimul phosphoryl
angiopoietin compet angiopoietin therebi suppress phosphoryl
also regul vascular endotheli protein tyrosin phosphatas ve-
ptp dephosphoryl therebi reduc activ
preclin model shown ve-ptp inhibit even presenc high
page analyst certif import disclosur
facet differenti potenti first
system administ drug diabet retinopathi
could potenti first treatment diabet retinopathi
system administr allow treatment eye someth possibl
current approv drug
current approv drug diabet retinopathi potent effect avail
intravitr ivt inject limit use doctor offic increas
regeneron eylea initi approv wet nov label expand
includ dme jul dr dme expans dr/ npdr possibl
roch lucenti receiv first approv wet jun label expand
includ dme aug dr dme feb dr apr
need chronic therapi asymptomat diseas increas treatment burden
oral avail could elimin limit expand usag
allow patient self-administ home
reduc treatment burden treat eye inject
page analyst certif import disclosur
self-administ patient drug dr
administ intravitr inject
self-administ patient via subcutan abdomin inject twice
per day morn second within hour morn dose
patient expect eat meal snack drink glass fluid
inject remain seat minut inject
anti-vegf therapi includ eylea lucenti off-label avastin wet
rvo dme dr administ via intravitr inject physician
inject may need given monthli everi month depend
sever diseas patient
eylea recommend dose mg ml microlit administ
intravitr inject monthli first inject follow mg ml via
intravitr inject everi month patient may need monthli dose
first month
lucenti mg ml mg/ml lucenti solut recommend dose
administ intravitr inject month
current approv treatment dr requir administr intravitr inject
doctor monthli everi month world treatment burden may less
channel check indic even quarterli inject consid frequent dr
page analyst certif import disclosur
approv anti-vegf treatment sale annual
use dr limit could better accept dr
approv treatment dr
reli anti-vegf therapi requir intravitr inject often
month initi less frequent dose especi real world
eylea panorama studi evalu everi everi month dose npdr
despit post multiple-billion sale world-wide doctor tell us use patient
diabet retinopathi especi non-prolif diabet retinopathi limit
report eylea sale come wet dme
reason gener center around treatment burden patient reluct commit chronic
therapi requir ivt inject especi diseas vision threaten
eylea lucenti sale million
avail self-administ subcutan inject chronic therapi dr
like prove much accept patient see usag accord doctor
page analyst certif import disclosur
facet differenti could produc addit
benefit address kidney complic diabet patient
high blood glucos high blood
pressur well progress diabet
microvascular diseas lead similar
complic retin glomerular
increas ve-ptp result
vascular destabil capillari loss
lead vascular leakag
neovascular lead retinopathi
eye nephropathi kidney
urinari albumin creatinin ratio uacr
patient proteinuria baselin
treatment appear result
improv uacr function month
progress diabet eye diabet kidney diseas suggest common patholog
process begin vascular destabil vasoregress end
vascular leakag neovascular mechanist could benefit
page analyst certif import disclosur
facet differenti market opportun larg
could effici way target dr patient
arpo estim patient diagnos npdr us anoth
eu row
total address market would includ undiagnos npdr would larger
patient us alon per arpo
number patient diagnos npdr us eu japan develop
avail viabl treatment option patient npdr like lead
market expans undiagnos npdr patient could diagnos
page analyst certif import disclosur
facet differenti patent life arpo pipelin long
limit number competitor develop
protect potenti
issu composit matter patent us expir
potenti subject hatch-waxman extens
previous protect potenti
issu composit matter patent us expir potenti subject
hatch-waxman extens
right exclus licens jun
page analyst certif import disclosur
clinicaltri gov search show trial diabet retinopathi
includ npdr pdr
roch lucenti drug current approv treat diabet retinopathi dr
regeneron eylea approv treatment dr patient diabet macular edema
base physician check drug see neglig amount usag dr
page analyst certif import disclosur
arpo thing need know
page analyst certif import disclosur
thing need know issu demonstr
suffici level clinic activ safeti patient dr npdr
demonstr suffici level clinic activ safeti patient
dr npdr like studi succeed
guggenheim view demonstr improv drss similar
level achiev lucenti studi howev exploratori endpoint
patient treat diabet macular edema also mechanist
valid potenti lead improv drss regeneron
roch antibodi act angiopoietin/
pathway target demonstr signific improv
drss combin anti-vegf studi evalu
treatment non-prolif diabet retinopathi improv
etdr dr sever score drss primari endpoint also differ
studi lead us believ outcom
studi could favor
page analyst certif import disclosur
drss fda accept endpoint approv measur progress
diabet diseas demonstr benefit
lucenti approv treatment diabet retinopathi measur
step improv drss studi patient dr dme
baselin studi enrol dr patient without dme evalu
improv baselin etdrs-drss
eylea approv dr patient dme came data base vivid
studi measur etdrs-drss evalu baselin everi month
panorama studi patient moder sever sever npdr drss
level measur proport patient improv drss
primari endpoint dose everi everi month
drss primari endpoint studi demonstr
benefit endpoint drss primari endpoint studi
page analyst certif import disclosur
chang baselin drss secondari endpoint
outcom similar benefit eye
result similar improv
improv drss month
mean drss similar across three arm
baselin /- combin
lucenti arm /- lucenti
/- arm
patient treat show posit
effect fellow eye well percentag
qualifi fellow eye chang
plu lucenti arm akb-
lucenti arm
long-term treatment durat could lead even
better outcom base drss
channel check indic chang
would look upon favor chang
lower end accompani
chang uacr
page analyst certif import disclosur
anti-vegf drug demonstr strong improv drss
howev mode administr limit use
lucenti demonstr
improv sham patient
dr dme
dr without dme
eylea panorama studi non-
npdr patient drss level
show eylea
treat patient
improv vs sham
eylea lucenti prescrib inform compani report
page analyst certif import disclosur
panorama phase studi eylea patient moder sever sever npdr drss mg weeksiai mg weeksal iai improv patient develop pdr/asnv develop develop
lucenti data show improv diabet retinopathi appear
continu time treatment
longer treatment durat could lead greater improv
studi studi
page analyst certif import disclosur
phase roch regeneron data support potenti
demonstr synergist effect treatment anti-vegf alon
roch rhhbi regeneron target
combin anti-vegf drug show improv drss
develop continu develop discontinu
howev neutral affect ve-ptp downstream inhibitor
ve-ptp inhibit activ regardless level
page analyst certif import disclosur
inactiv ve-ptp target
differ aspect pathway
receptor locat vascular endotheli cell modul vascular
permeabl phosphoryl suppress vascular leakag promot vascular
stabil angiopoietin stimul phosphoryl angiopoietin
compet angiopoietin suppress also dephosphoryl ve-
ptp whose inhibit even presenc angiopoietin restor activ
neutral affect ve-ptp downstream inhibitor though
anti-vegf drug work dme dr dme ideal ve-ptp inhibit
activ regardless level
page analyst certif import disclosur
phase studi npdr evalu drss primari endpoint
renal function one secondari endpoint
studi evalu activ patient moderate-to-sever
patient receiv mg once- twice-daili month
primari endpoint improv drss week
secondari endpoint evalu develop dme/ pdr dr progress renal
enrol began jun data expect
page analyst certif import disclosur
guggenheim secur llc clinicaltri gov
page analyst certif import disclosur
macular edema dme moder sever npdr without dme double-mask active-controlledrandom double-mask placebo-controlledtreat mg bid subcutan inject plu ranibizumab mg monthli intravitr mg bid subcutan inject plu ranibizumab mg monthli intravitr injection-placebo subcutan inject bid plu ranibizumab mg monthli intravitr bid subcutan qd subcutan injection-placebo bid subcutan injectioninclusion-adult year age-diagnosi diabet mellitu type type vision studi eye determin primarili result dme-definit retin thicken due diffus dme involv central macula studi eye-centr subfield thick least sdoct presenc intraretin fluid studi eye-etdr bcva letter score studi eye-adult year age-subject moder sever npdr etdr level inclus -no evid central involv dme-etdr bcva letter score snellen better exclusion-hemoglobin screening-histori non infecti uveitis-decreas visual acuiti due caus dme studi eye-histori follow studi eye prior par plana vitrectomi ocular surgeri within month prior day yag capsulotomi within month prior day prp focal laser within month prior day anticip need prp cours studi prior intravitr subtenon periocular steroid therapi within month prior day prior treatment intravitr anti-vascular endotheli growth factor vegf treatment within week prior day diseas dr may caus substanti reduct visual acuiti includ iri neovascular retin detach visual signific epiretin membran vitreou hemorrhag fibrosi ocular inflamm uveiti retin inflammatori infecti diseases-evid neovascular clinic examin imaging-hemoglobin screening-sever acut chronic medic psychiatr condit laboratori abnorm may increas risk associ studi participationprimari outcomemean chang baselin sdoct-measur cst monthspercentag subject improv drss step weekssecondari outcomes-mean chang baselin etdr bcva months-secondari outcom includ improv drss eye week sever advers events-chang baselin clinic laboratori assay site
non-ocular advers event studi mostli mild transient
common non-ocular dizzi nausea fatigu vomit cough
dizzi nausea fatigu higher patient receiv vs lucenti
dizzi fatigu event mild mani transient
durat day none result patient withdraw treatment
asymptomat blood pressur reduct occur first dose
mean systol blood pressur decreas mmhg min mmhg min
mean baselin systol blood pressur mmhg mean chang systol
blood pressur end week treatment similar
mmhg lucenti arm mmhg
page analyst certif import disclosur
